相似文献
1
Lipid- and Polymer-Based Nanoparticle Systems for the Delivery of CRISPR/Cas9.
J Drug Deliv Sci Technol. 2021 Oct;65. doi: 10.1016/j.jddst.2021.102728. Epub 2021 Jul 11.
2
Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Drug Deliv Transl Res. 2023 May;13(5):1500-1519. doi: 10.1007/s13346-023-01320-z. Epub 2023 Mar 29.
3
Nanocarriers: A novel strategy for the delivery of CRISPR/Cas systems.
Front Chem. 2022 Jul 26;10:957572. doi: 10.3389/fchem.2022.957572. eCollection 2022.
4
Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing.
Front Genet. 2021 May 12;12:673286. doi: 10.3389/fgene.2021.673286. eCollection 2021.
5
Lipid-, Inorganic-, Polymer-, and DNA-Based Nanocarriers for Delivery of the CRISPR/Cas9 system.
Chembiochem. 2023 Aug 15;24(16):e202300180. doi: 10.1002/cbic.202300180. Epub 2023 Jul 25.
6
Advances in CRISPR/Cas9 Technology for in Vivo Translation.
Biol Pharm Bull. 2019;42(3):304-311. doi: 10.1248/bpb.b18-00811.
7
Delivery Tools for Clustered Regularly Interspaced Short Palindromic Repeat/Associated Protein 9-Mediated Inhibition of Hepatitis B Virus Infection: An Update.
Front Microbiol. 2022 Jul 1;13:953218. doi: 10.3389/fmicb.2022.953218. eCollection 2022.
8
Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Cancer Commun (Lond). 2022 Dec;42(12):1257-1287. doi: 10.1002/cac2.12366. Epub 2022 Oct 9.
9
A CRISPR/Cas9 based polymeric nanoparticles to treat/inhibit microbial infections.
Semin Cell Dev Biol. 2019 Dec;96:44-52. doi: 10.1016/j.semcdb.2019.04.007. Epub 2019 May 23.
10
CRISPR-based therapeutics: current challenges and future applications.
Trends Pharmacol Sci. 2022 Feb;43(2):151-161. doi: 10.1016/j.tips.2021.10.012. Epub 2021 Dec 21.
引用本文的文献
1
CRISPR/Cas9 in colorectal cancer: Revolutionizing precision oncology through genome editing and targeted therapeutics.
Iran J Basic Med Sci. 2025;28(10):1279-1300. doi: 10.22038/ijbms.2025.87531.18902.
2
Microfluidic Platforms for Ex Vivo and In Vivo Gene Therapy.
Biosensors (Basel). 2025 Aug 4;15(8):504. doi: 10.3390/bios15080504.
3
Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects.
Expert Rev Mol Med. 2025 Mar 31;27:e16. doi: 10.1017/erm.2025.10.
4
Improving the use of CRISPR/Cas9 gene editing machinery as a cancer therapeutic tool with the help of nanomedicine.
3 Biotech. 2025 Jan;15(1):17. doi: 10.1007/s13205-024-04186-1. Epub 2024 Dec 19.
5
State of the art CRISPR-based strategies for cancer diagnostics and treatment.
Biomark Res. 2024 Dec 18;12(1):156. doi: 10.1186/s40364-024-00701-x.
6
Biodynamer Nano-Complexes and -Emulsions for Peptide and Protein Drug Delivery.
Int J Nanomedicine. 2024 May 19;19:4429-4449. doi: 10.2147/IJN.S448578. eCollection 2024.
7
Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment.
Biomater Res. 2024 Apr 30;28:0023. doi: 10.34133/bmr.0023. eCollection 2024.
8
Revolutionizing Neurological Disorder Treatment: Integrating Innovations in Pharmaceutical Interventions and Advanced Therapeutic Technologies.
Curr Pharm Des. 2024;30(19):1459-1471. doi: 10.2174/0113816128284824240328071911.
9
An Innovative Polymeric Platform for Controlled and Localized Drug Delivery.
Pharmaceutics. 2023 Jun 23;15(7):1795. doi: 10.3390/pharmaceutics15071795.
10
Recent Genome-Editing Approaches toward Post-Implanted Fetuses in Mice.
BioTech (Basel). 2023 May 11;12(2):37. doi: 10.3390/biotech12020037.
本文引用的文献
1
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
N Engl J Med. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
2
Engineering precision nanoparticles for drug delivery.
Nat Rev Drug Discov. 2021 Feb;20(2):101-124. doi: 10.1038/s41573-020-0090-8. Epub 2020 Dec 4.
3
CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy.
Sci Adv. 2020 Nov 18;6(47). doi: 10.1126/sciadv.abc9450. Print 2020 Nov.
4
Thermosensitive Exosome-Liposome Hybrid Nanoparticle-Mediated Chemoimmunotherapy for Improved Treatment of Metastatic Peritoneal Cancer.
Adv Sci (Weinh). 2020 Jul 29;7(18):2000515. doi: 10.1002/advs.202000515. eCollection 2020 Sep.
5
Engineering Smart Targeting Nanovesicles and Their Combination with Hydrogels for Controlled Drug Delivery.
Pharmaceutics. 2020 Sep 7;12(9):849. doi: 10.3390/pharmaceutics12090849.
6
CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Adv Drug Deliv Rev. 2020;158:17-35. doi: 10.1016/j.addr.2020.07.015. Epub 2020 Jul 21.
7
Polymeric vehicles for nucleic acid delivery.
Adv Drug Deliv Rev. 2020;156:119-132. doi: 10.1016/j.addr.2020.06.014. Epub 2020 Jun 23.
8
Recent Advances in CRISPR/Cas9 Delivery Strategies.
Biomolecules. 2020 May 30;10(6):839. doi: 10.3390/biom10060839.
9
Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer.
Nanoscale. 2020 May 21;12(19):10854-10862. doi: 10.1039/d0nr00523a.
10
Bioinspired exosome-like therapeutics and delivery nanoplatforms.
Biomaterials. 2020 Jun;242:119925. doi: 10.1016/j.biomaterials.2020.119925. Epub 2020 Mar 2.
Zotero 插件